What is the recommended dose of diphenhydramine (antihistamine) for intravenous (IV) injection in a 10-year-old child weighing 27 kilograms (kg)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diphenhydramine IV Dosing for a 27 kg, 10-Year-Old Child

For this 27 kg, 10-year-old child, administer 27-54 mg of diphenhydramine IV (1-2 mg/kg), not exceeding 50 mg as the maximum single dose, given slowly at a rate not exceeding 25 mg/min. 1, 2, 3

Specific Dose Calculation

  • Weight-based dosing: At 1-2 mg/kg for a 27 kg child, the calculated range is 27-54 mg 1, 2
  • Maximum dose cap: Despite the calculated upper range of 54 mg, the maximum single dose should not exceed 50 mg regardless of weight 2, 3
  • Practical recommendation: Administer 50 mg IV as the appropriate dose for this child, given slowly 3

Critical Administration Requirements

  • Rate of administration: Must not exceed 25 mg/min to prevent seizures 1, 3
  • Monitoring: Watch closely for respiratory depression and sedation, particularly if other sedatives are being used concurrently 1, 2
  • Route verification: Ensure IV access is secure before administration 3

Age-Specific Considerations

This 10-year-old falls into the 6-12 year age group, where:

  • The full 1-2 mg/kg dosing range can be used (unlike younger children who should receive the lower end at 1 mg/kg) 2
  • The 50 mg maximum still applies 2, 3
  • For comparison, chlorphenamine dosing for this age group would be 5 mg, but diphenhydramine follows different dosing parameters 4

Clinical Context and Safety Warnings

Diphenhydramine should NEVER be used as first-line therapy for anaphylaxis—epinephrine is always the primary treatment 1, 5, 2. Diphenhydramine is strictly second-line adjunctive therapy 1, 2.

Serious Adverse Events to Avoid:

  • Rapid IV push can precipitate seizures—always administer slowly 1, 2
  • Cardiac arrest has been reported following IV diphenhydramine administration, even at therapeutic doses (1.25 mg/kg) in vulnerable populations 6
  • Respiratory suppression is a significant risk, especially with concurrent sedatives 1, 2

Common Pitfalls

  • Do not exceed 25 mg/min infusion rate—this is the most critical safety parameter 3
  • Do not give more than 50 mg as a single dose even though weight-based calculation may suggest higher 2, 3
  • Do not use as monotherapy for anaphylaxis—always ensure epinephrine has been given first 1, 5
  • Do not assume oral dosing equivalence—IV administration carries higher risk and requires slower administration 3, 6

FDA-Approved Dosing Reference

The FDA label specifies for pediatric patients (excluding premature infants and neonates): 5 mg/kg/24 hr or 150 mg/m²/24 hr, with a maximum daily dosage of 300 mg, divided into four doses and administered IV at a rate generally not exceeding 25 mg/min 3. For a single dose in this 27 kg child, this translates to approximately 33.75 mg per dose (135 mg ÷ 4 doses), though the guideline-based 1-2 mg/kg approach with a 50 mg cap is more commonly used in acute settings 1, 2, 3.

References

Guideline

Diphenhydramine Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diphenhydramine Syrup Dosing in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antihistamine Dosing for Pediatric Allergic Symptoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cardiac Arrest Following the Administration of Intravenous Diphenhydramine for Sedation to an Infant With Congenital Heart Disease.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.